Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.030
+0.032 (3.17%)
At close: Sep 17, 2026, 4:00 PM EDT
1.040
+0.010 (0.97%)
After-hours: Sep 17, 2026, 7:57 PM EDT
Ocugen Employees
Ocugen had 116 employees as of December 31, 2025. The number of employees increased by 21 or 22.11% compared to the previous year.
Employees
116
Change (1Y)
21
Growth (1Y)
22.11%
Revenue / Employee
$39,491
Profits / Employee
-$705,267
Market Cap
349.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 116 | 21 | 22.11% |
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Enanta Pharmaceuticals | 120 |
| Agenus | 81 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 63 |
| X4 Pharmaceuticals | 45 |
| Compass Therapeutics | 39 |
| DiaMedica Therapeutics | 35 |
OCGN News
- 2 days ago - Ocugen Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 days ago - Ocugen price target lowered to $9.50 from $10 at H.C. Wainwright - TheFly
- 16 days ago - Ocugen doses first patient in OCU410 trial - TheFly
- 16 days ago - Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 23 days ago - Ocugen to Participate in Upcoming September Investor and Industry Conferences - GlobeNewsWire
- 4 weeks ago - Ocugen Proxy statement: Proxy filing - Filings
- 5 weeks ago - Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 6 weeks ago - Ocugen Earnings Call Transcript: Q2 2026 - Transcripts